This page uses content from Wikipedia and is licensed under CC BY-SA.


Clinical data
Routes of
ATC code
  • none
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass425.39 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Spiradoline (U-62066) is a drug which acts as a highly selective κ-opioid agonist.[1] It has analgesic,[2] diuretic,[3] and antitussive effects,[4] and produces subjective effects in animals similar to those of ketazocine and alazocine.[5] The main effect in humans is sedation, along with analgesic and diuretic effects, but significant side effects such as dysphoria and hallucinations have stopped it from being used clinically.[6]

See also


  1. ^ Vonvoigtlander, P. F; Lewis, R. A (1988). "Analgesic and mechanistic evaluation of spiradoline, a potent kappa opioid". The Journal of Pharmacology and Experimental Therapeutics. 246 (1): 259–62. PMID 2839665.
  2. ^ Kunihara, M; Ohyama, M; Nakano, M; Hayashi, S (1989). "Analgesic activity of spiradoline mesylate (U-62,066E), a kappa opioid agonist in mice". Life Sciences. 45 (13): 1191–8. doi:10.1016/0024-3205(89)90508-0. PMID 2796604.
  3. ^ Yamada, K; Imai, M; Yoshida, S (1989). "Mechanism of diuretic action of U-62,066E, a kappa opioid receptor agonist". European Journal of Pharmacology. 160 (2): 229–37. doi:10.1016/0014-2999(89)90495-0. PMID 2547626.
  4. ^ Kamei, J; Tanihara, H; Kasuya, Y (1990). "Antitussive effects of two specific kappa-opioid agonists, U-50,488H and U-62,066E, in rats". European Journal of Pharmacology. 187 (2): 281–6. doi:10.1016/0014-2999(90)90014-w. PMID 2272363.
  5. ^ Holtzman, S. G (2000). "Further characterization of the discriminative stimulus effects of spiradoline". Pharmacology Biochemistry and Behavior. 66 (3): 517–22. doi:10.1016/s0091-3057(00)00172-6. PMID 10899364.
  6. ^ Wadenberg, M. L (2003). "A review of the properties of spiradoline: A potent and selective kappa-opioid receptor agonist". CNS Drug Reviews. 9 (2): 187–98. PMID 12847558.